Combined sewer overflow mitigation through SUDS - A review on modelling practices, scenario elaboration, and related performances.

Hydrologic-hydraulic modelling of urban catchment is an asset for land managers to simulate Sustainable Urban Drainage Systems (SUDS) implementation to fulfil combined sewer overflow (CSO) regulations. This review aims to assess the current practices in modelling SUDS scenarios at large scale for CSO mitigation encompassing every stage of the modelling process from the choice of the equation to the validation of the initial state of the urban system, right through to the elaboration, modelling, and selection of SUDS scenarios to evaluate their performance on CSO. Through a quantitative and qualitative analysis of 50 published studies, we found a diversity of choices when modelling the status quo of the urban system. Authors generally do not explain the modelling processes of slow components (deep infiltration, groundwater infiltration) and interconnexion between SUDS and the sewer system. In addition, only a few authors explain how CSO structures are modelled. Furthermore, the modelling of SUDS implementation at catchment scale is highlighted in the 50 studies retrieved with three different approaches going from simplified to detailed. SUDS modelling choices seem to be consistent with the objectives: studies focusing on dealing with several objectives at the time typically opt for a complex system configuration that includes the surface processes, network, CSO, SUDS, and often the soil and/or groundwater components. Conversely, authors who have selected a basic configuration generally aim to address a single, straightforward question (e.g., which type of SUDS). However, elaboration and selection of scenarios for CSO mitigation is mainly based on local constraints, which does not allow hydrological performance to be directly optimised. In conclusion, to improve current practices in modelling SUDS scenarios at large scale for CSO mitigation, authors suggest to: (i) improve clear practices of CSO modelling, calibration and validation at the urban catchment scale, (ii) develop methods to optimize the performance of scenarios for CSO mitigation using hydrological drivers, and (iii) improve parsimonious and user-friendly models to simulate SUDS scenarios in a context of data scarcity.

Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis.

OBJECTIVE: To describe the pharmacokinetic (PK) profile of anidulafungin and to evaluate its concentration in the peritoneal fluid (PF) of patients suspected of suffering from peritoneal infection undergoing abdominal surgery, in order to ensure that therapeutic levels are achieved within the peritoneal cavity. METHODS: A descriptive, open, prospective, observational, multicentre and non-interventional study was performed. Anidulafungin was used at conventional doses. Blood and PF samples were obtained on day 2 of treatment or on any of the following days. RESULTS: A total of 31 patients in a serious clinical condition, as demonstrated by high mean clinical severity scale scores (APACHE II and SOFA scores), were included in the study. The mean area under the curve (AUC) in PF was 30% (31±19%) of that determined in the plasma and the maximum concentration (Cmax) reached in PF (mg/l) was close to 1 (0.9±0.5). No adverse effects were observed in any of the 31 patients. CONCLUSIONS: Anidulafungin at conventional doses reaches PF concentrations that exceed the minimum inhibitory concentration of the usual Candida spp, which explains the proven efficacy of this echinocandin in the treatment of Candida peritonitis in critically ill patients.

Aplicación intracoronaria de levosimendán en la prueba de fracción de flujo de reserva coronaria (Simdax) / Intracoronary administration of levosimendan in the coronary fractional flow reserve test

Introducción: El estudio hemodinámico de una estenosis coronaria de severidad intermedia mediante la prueba de fracción de flujo de reserva (FFR) coronaria es fundamental en términos de eventos cardiovasculares principales a corto y largo plazo. Actualmente, no se ha publicado en este contexto la aplicación intracoronaria de levosimendán. Objetivos: Determinar los efectos hemodinámicos de la administración intracoronaria de levosimendán como vasodilatador en la prueba FFR, comparado contra adenosina intracoronaria. Material y métodos: Se estudiaron mediante FFR 48 lesiones intermedias en las coronarias epicárdicas principales. Resultados: De las 48 lesiones valoradas con FFR en relación con la aplicación de adenosina versus levosimendán intracoronarios, el porcentaje de estenosis coronaria fue del 55.83 (± 11.64), FFR adenosina intracoronaria 0.8633 (± 0.1130) y FFR levosimendán intracoronario 0.8652 (± 0.1090); coeficiente de correlación 0.9859 y correlación cuadrática 0.9720. Demostrando que la inducción de vasodilatación es semejante, incluyendo casos positivos para revascularización con relación FFR < 0.80. Conclusiones: El levosimendán intracoronario en la prueba FFR presentó semejanza en la valoración de las estenosis coronarias intermedias, comparado con adenosina intracoronaria. El levosimendán representa una alternativa favorable en la inducción de hiperemia coronaria, para normar decisiones de revascularización mediante asistencia fisiológica.

Aims: The hemodynamic study of a coronary stenosis of intermediate severity, by testing fraction flow reserve (FFR) is essential in terms of major cardiovascular events in the short and long term. Currently not published in this context the intracoronary application of levosimendan. Objectives: To determine the hemodynamic effects of intracoronary administration of levosimendan, a vasodilator in the FFR test, compared with intracoronary adenosine. Material and methods: Were evaluated by FFR, 48 intermediate lesions in major epicardial coronary arteries. Results: Of the 48 lesions with FFR assessed, the application of adenosine versus intracoronary levosimendan, the percentage of coronary stenosis was 55.83 (± 11.64), intracoronary adenosine FFR 0.8633 (± 0.1130) and 0.8652 FFR intracoronary levosimendan (± 0.1090) correlation coefficient of 0.9859 and 0.9720 quadratic correlation. Demonstrating that induction of vasodilatation is similar, including revascularization positive cases compared FFR < 0.80. Conclusions: Intracoronary levosimendan in the FFR test showed similarity in the assessment of intermediate coronary stenosis compared with intracoronary adenosine. Levosimendan is an excellent alternative in the induction of coronary hyperemia decisions to regulate physiological revascularization with assistance.

Post-Earthquake Injuries Treated at a Field Hospital ù Haiti, 2010

La "University of Miami Global Institute/Project Medishare" (UMGI/PM) a créé le premier hôpital de campagne à Port-au-Prince, en Haïti, après le séisme. Afin de caractériser les blessures et les interventions chirurgicales effectuées par l'UMGI/PM et d'évaluer les besoins spéciaux médicaux, chirurgicaux et de réadaptation, l'UMGI/PM et le "Centers for Disease Control and Prevention" (CDC) mènent une analyse rétrospective de tous les dossiers médicaux de malades disponibles pour la période du 13 janvier au 28 mai 2010. Le premier article de cette revue décrit les résultats de cette analyse et présente les données quantitatives obtenues.

Muerte súbita como forma de presentación de un Síndrome de Conn / Sudden death as presentation of Conn’s syndrome

Los pacientes con hiperaldosteronismo secundario a adenoma suprarrenal (síndrome de Conn) se suelen encontrar asintomáticos o con escasos síntomas debidos a la hipertensión arterial per se o a hipokaliemia. Presentamos un caso de síndrome de Conn no conocido cuyo comienzo fue una muerte súbita con desarrollo posterior de encefalopatía postanóxica y desenlace fatal (AU)

Patients with hyperaldosteronism secondary to an adrenal adenoma (Conn’s syndrome) are usually asymptomatic or evidence but few symptoms due to arterial hypertension per se or to hypokaliaemia. We present one case of previously undiagnosed Conn’s syndrome presenting as sudden death with ensuing development of post-anoxic encephalopathy and fatal outcome (AU)

Hepatitis B vaccination coverage among United States children.

BACKGROUND: In 1991 the Advisory Committee on Immunization Practices recommended vaccination of all infants with three doses of hepatitis B virus vaccine (HepB) by 18 months of age as a key component of a comprehensive strategy to eliminate hepatitis B virus transmission in the United States. The American Academy of Pediatrics and the American Academy of Family Physicians published similar recommendations soon afterward. METHODS: Data were obtained from the National Immunization Survey, a survey that began in 1994 and is conducted quarterly by the Centers for Disease Control and Prevention to estimate vaccination coverage among noninstitutionalized US children 19 to 35 months of age. RESULTS: The 1999 National Immunization Survey data indicate that approximately 88.1% (95% confidence interval, 87.4, 88.8) of children 19 to 35 months of age had received at least three doses of HepB (HepB3). There has been a consistent increase in HepB3 coverage since 1994. However, the rate of increase has slowed in recent years and HepB3 coverage remains lower than coverage attained with three doses of diphtheria-tetanus-pertussis and Haemophilus influenzae vaccines. HepB3 coverage varied slightly by race/ethnicity and was highest among white and Asian children (89%). Coverage also varied by state; 26 states had levels of at least 90%. CONCLUSIONS: Since the 1991 recommendations for universal hepatitis B vaccination, there has been a dramatic increase in coverage levels among children 19 to 35 months of age. However, the Childhood Immunization Initiative goal of 90% coverage has not been reached. Therefore continued efforts are needed to protect US children against this serious but preventable infection.

Efectos de la optimización del transporte de oxígeno sobre la morbimortalidad en el postoperatorio de cirugía cardíaca / Hemodynamic optimization and morbimortality after heart surgery

Fundamento. La contracción de una deuda de oxígeno se ha asociado con peores resultados clínicos, y se ha hipotetizado que la optimización del transporte de oxígeno (DO2) mejoraría dichos resultados. En el presente estudio optimizamos el DO2 y valoramos su efecto sobre la morbimortalidad y estancia media en la unidad de medicina intensiva (UCI).Métodos. Estudio prospectivo, intervencional, aleatorizado y controlado con 390 enfermos sometidos a cirugía cardíaca con circulación extracorpórea (CEC), ingresados en nuestra UCI: el grupo optimizado (GO) incluía a 181 enfermos y el grupo control (GC) a 209. La optimización del GO se llevó a cabo en las primeras 8 h del postoperatorio inmediato, logrando una saturación venosa mixta de oxígeno (SvO2) 70 por ciento. Todos los enfermos ingresaron con un catéter en la arteria pulmonar y se registraron las mediciones de las variables cardiorrespiratorias a las 0, 4 y 8 h de su ingreso. Resultados. Los pacientes del GO revelaron una SvO2 y un DO2 significativamente mayores que los del GC, a pesar de lo cual no observamos ninguna diferencia significativa en las variables estudiadas, respecto al GC. Los enfermos que fallecieron presentaron -en relación con los que sobrevivieron- menores DO2 y SvO2, con cifras de DO2 cercanas a las del DO2 crítico, y precisaron con más frecuencia fármacos inotrópicos y balón de contrapulsación intraaórtica (BCIA). Conclusiones. La optimización del DO2 en el postoperatorio inmediato de cirugía cardíaca no logró disminuir la morbimortalidad ni la estancia media en la UCI; los pacientes que fallecieron contrajeron una deuda de oxígeno, fundamentalmente por fallo cardíaco de bomba, que les incapacitó para conseguir un DO2 superior al DO2 crítico (AU)

ATP6H, a subunit of vacuolar ATPase involved in metal transport: evaluation in canine copper toxicosis.

Copper toxicosis (CT), resulting in liver disease, occurs commonly in Bedlington terriers. Canine CT is of particular interest because identification of the causative gene may lead to the discovery of another important gene in the copper transport pathway possibly related to human copper diseases not yet identified. Homologs of the copper transporting ATPase ATP7B, defective in Wilson disease, and the copper chaperone ATOX1 were potential candidates, but both have been excluded. The CT locus in Bedlington terriers has been mapped to canine chromosome region CFA10q26, which has a syntenic human chromosome region, HAS2p13-21. The gene ATP6H, for human vacuolar proton-ATPase subunit M9.2, is associated with copper and iron transport in yeast and has been mapped to HAS2p21 and suggested as a candidate gene for CT. We cloned canine ATP6H, which encodes a predicted protein with 99% amino acid sequence identity to the orthologous human protein. Canine ATP6H shows a conserved potential metal binding site, CSVCC, and a glycosylation site, NET. The canine ATP6H is organized into four exons, with a 246-bp open reading frame. Sequence analysis of the coding regions showed no mutations in ATP6H from genomic DNA of an affected dog. We have also identified two, apparently non-transcribed canine ATP6H pseudogenes. Mapping of the true ATP6H gene and a marker closely linked to the CT locus on a canine radiation hybrid panel indicted lack of close physical association. We have therefore excluded canine ATP6H as a candidate gene for canine copper toxicosis, indicating that some other unidentified gene is responsible for this copper storage disease.

Vaccination status of children in the Women, Infants, and Children (WIC) Program: are we doing enough to improve coverage?

BACKGROUND: Vaccination-promoting strategies in the Supplemental Nutrition Program for Women, Infants, and Children (WIC) have been shown to produce dramatic improvements in coverage and other health outcomes. OBJECTIVES: To determine national and state-specific population-based vaccine coverage rates among preschool children who participate in the WIC program, and to describe the strategies for promoting vaccination in WIC. DESIGN/METHODS: Demographic data, WIC participation, and vaccination histories for children aged 24 to 35 months in 1999 were collected from parents through the National Immunization Survey. The healthcare providers for the children in the survey were contacted to verify and complete vaccination information. We defined children as up-to-date (UTD) if they had received four doses of diphtheria and tetanus toxoids and pertussis vaccine (DPT), three doses of poliovirus vaccine, one dose of measles-mumps-rubella vaccine (MMR), and three doses of Haemophilus influenzae type b vaccine (Hib) by 24 months. Description of state-level vaccination-promoting activities in WIC was collected through an annual survey completed by the state WIC and immunization program directors. RESULTS: Complete data were collected on 15,766 children, of whom 7783 (49%) participated in WIC sometime in their lives. Nationally, children who had ever participated in WIC were less well-immunized at 24 months compared to children who had not: 72.9% UTD (95% CI, 71.3-74.5) versus 80.8% UTD (95% CI, 79.5-82.1), respectively. In 42 states, 24-month coverage among WIC participants was less than among non-WIC participants, including 13 states where the difference was > or = 10%. Vaccination activities linked with WIC were reported from 76% of 8287 WIC sites nationwide. States conducting more-frequent interventions and reaching a higher proportion of WIC participants had 40% higher vaccination coverage levels for the WIC participants in that state (p<0.05). CONCLUSIONS: Children served by WIC remain less well-immunized than the nation's more-affluent children who do not participate in WIC. Thus, WIC remains a good place to target these children. This study provides evidence that fully implemented WIC linkage works to improve vaccination rates. Strategies that have been shown to improve the vaccination coverage levels of WIC participants should be expanded and adequately funded to protect these children.

National, state, and urban area vaccination coverage levels among children aged 19-35 months--United States, 1998.

PROBLEM/CONDITION: High vaccination levels in the population are necessary to decrease disease transmission and prevent disease; therefore, an important component of the U.S. vaccination program is the assessment of vaccination coverage. Current goals are for > or = 90% coverage with recommended vaccines during the first 2 years of life. REPORTING PERIOD: January-December 1998. DESCRIPTION OF SYSTEMS: The National Immunization Survey (NIS) is an ongoing, random-digit-dialed telephone survey that gathers vaccination coverage data for children aged 19-35 months in all 50 states and 28 urban areas. Vaccination coverage rates derived from NIS data are adjusted statistically for households with multiple telephone lines, household nonresponse, the proportion of households without telephones, and vaccination provider nonresponse. The results were also adjusted to match the known total population of children in each survey area. RESULTS: On the basis of NIS data, national coverage was > or = 90% for three doses of poliovirus vaccine (Polio), three doses of Haemophilus influenzae type b vaccine (Hib), and one dose of measles-containing vaccine (MCV). Coverage was the highest ever reported for four doses of any diphtheria and tetanus toxoids and pertussis vaccine (DTP) (i.e., diphtheria and tetanus toxoids and pertussis vaccine, diphtheria and tetanus toxoids [DT], or diphtheria and tetanus toxoids and acellular pertussis vaccine [DTaP]) (83.9%), three doses of hepatitis B vaccine (Hep B, 87.0%), and one dose of varicella vaccine (43.2%). The number of states achieving the > or = 90% goal was 47 for three doses of Hib, 40 for three doses of Polio, 40 for one dose of MCV, nine for three doses of Hep B, and seven for four doses of DTP. Proportionally fewer urban areas achieved the > or = 90% goal: 23 of 28 for three doses of Hib, 13 for three doses of Polio, 16 for one dose of MCV, five for three doses of Hep B, and one for four doses of DTP. No state or urban area has yet achieved the > or = 90% goal for varicella. INTERPRETATION: Findings from the 1998 NIS indicate that national vaccination coverage levels for routinely recommended childhood vaccines are at the highest levels ever reported. However, substantial variation in coverage remains at the state and urban area levels. PUBLIC HEALTH ACTIONS: The public health community and vaccination providers in areas with low coverage should intensify their efforts to implement recommended strategies for increasing vaccination coverage to ensure that children are equally well protected throughout the United States.

Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series.

CONTEXT: The association between infant age at initiation of hepatitis B vaccination and completion of the 3-dose hepatitis B vaccination series is unclear. OBJECTIVE: To assess the association between administration of the first dose of hepatitis B vaccine within 7 days of birth and completion of the hepatitis B vaccine series and the 4:3:1:3 vaccine series (4 doses of diphtheria-tetanus-pertussis vaccine, 3 doses of polio vaccine, 1 dose of measles-containing vaccine, and 3 doses of Haemophilus influenzae type b vaccine). DESIGN, SETTING, AND PARTICIPANTS: Analysis of data from the 1998 National Immunization Survey, a random-digit-dialing telephone survey (n = 34,480 completed interviews) of parents of children aged 19 to 35 months from 50 states and 28 selected urban areas in the United States that included a provider record check mail survey. MAIN OUTCOME MEASURES: Percentage of infants who received at least 3 doses of hepatitis B vaccine and percentage who received the 4:3:1:3 vaccine series, by age at receipt of the first dose of hepatitis B vaccine. RESULTS: Overall, 86.9% of children 19 to 35 months of age in 1998 received 3 or more doses of hepatitis B vaccine, and 79.9% completed the 4:3:1:3 vaccine series. Multivariate analysis indicated that, compared with children who received the first hepatitis B vaccine dose within 7 days of birth, odds ratios (ORs) for not completing the 3-dose hepatitis B vaccine series among children who received the first dose at 8 to 41 days, 42 to 91 days, 92 to 182 days, 183 to 273 days, and 274 or more days of age were 2.4 (95% confidence interval [CI], 2.0-3.0), 7.8 (95% CI, 6.5-9.3), 9.6 (95% CI, 7.0-13. 3), 18.3 (95% CI, 12.0-28.0), and 46.6 (95% CI, 33.7-64.5), respectively; ORs for not completing the 4:3:1:3 vaccine series among these same groups were 1.0 (95% CI, 0.8-1.1), 1.0 (95% CI, 0. 8-1.1), 1.7 (95% CI, 1.3-2.3), 3.8 (95% CI, 2.6-5.6), and 4.0 (95% CI, 2.9-5.5), respectively. CONCLUSION: Administration of the first dose of hepatitis B vaccine at birth is associated with increased likelihood of completion of the hepatitis B vaccination series. JAMA. 2000;284:978-983

Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics.

Pediatric patients on dialysis should receive all the vaccines currently recommended by the ACIP and the AAP for healthy children, except the oral polio vaccine (34, 35). Adult patients should receive the hepatitis B vaccine series, pneumococcal vaccine, yearly influenza vaccinations, tetanus-diphtheria toxoids, and varicella vaccine, if they are susceptible (33, 48, 69). Vaccines are well tolerated by these patients (33), but higher doses and/or additional boosters may be required periodically to adequately protect dialysis patients from vaccine-preventable diseases (33, 36, 37, 82, 83). Following vaccination, antibody concentrations for hepatitis B vaccine should be measured annually and booster doses administered when antibody concentrations fall below protective levels (33, 38). Although both children and adults on dialysis may show an impaired and/or delayed immunologic response to certain antigens, particularly hepatitis B virus and S. pneumoniae, appropriate immunizations can significantly reduce the risk of serious complications from vaccine-preventable diseases (11, 84). Because the protection these vaccines provide may be incomplete or transient, infection control strategies at hospitals and other health care facilities should be implemented simultaneously. Health care providers are encouraged to assess each patients need for vaccinations individually and formulate immunization strategies early in the course of progressive renal disease, ideally before the patient requires dialysis.

Progress in coverage with hepatitis B vaccine among US children, 1994-1997.

OBJECTIVES: This study was done to assess progress in hepatitis B vaccination of children from 1994 through 1997. METHODS: We used data from the National Immunization Survey (NIS), a random-digit-dialed telephone survey that includes a mail survey to verify vaccination providers' records. The NIS is conducted in 78 geographic areas (50 states and 28 selected urban areas) in the United States. RESULTS: A total of 32,433 household interviews were completed in the 1997 NIS. An estimated 83.7% of children aged 19 to 35 months received 3 or more doses of hepatitis B vaccine. Coverage with 3 doses was greater (86.7%) among children in states that had day care entry requirements for hepatitis B vaccination than among children in states without such requirements (83.0%) and was greater among children from families with incomes at or above the poverty level (85.0%) than among children below the poverty level (80.6%). Hepatitis B vaccination of children increased from 1994 through 1996, from 41% to 84%, but coverage reached a constant level of 84% to 85% in 1996/97. CONCLUSION: Although substantial progress has been made in fully vaccinating children against hepatitis B, greater efforts are needed to ensure that all infants receive 3 doses of hepatitis B vaccine.

Vaccines for Children program, United States, 1997.

OBJECTIVES: 1) To determine the proportion of preschool children receiving immunizations from providers enrolled in the Vaccines for Children (VFC) program; 2) to assess whether their immunization providers serve as their medical home for primary care; and 3) to examine the relationship between various provider characteristics and immunization status. DESIGN: Two-phase national survey consisting of parent interviews verified by provider record check. SETTING: A total of 78 survey areas (50 states, the District of Columbia, and 27 urban areas). PATIENTS OR OTHER PARTICIPANTS: Noninstitutionalized children from 19 to 35 months of age in 1997. INTERVENTIONS: None. OUTCOME MEASURES: VFC penetration rate (the percentage of children who received all or some vaccines from a VFC-enrolled provider); the frequency with which children received all or some vaccines within a medical home; the number of parent-reported immunization providers; and 4:3:1:3 up-to-date status at 19 to 35 months of age. RESULTS: OFF 28 298 children interviewed for whom consent to contact providers was obtained, complete provider data were available for 21 522 (76%). Of these children, approximately 75% received all or some immunizations from a VFC-enrolled provider, 73% received all or some immunizations within a medical home, and 75% had one immunization provider. Children received all or some immunizations from a VFC-enrolled provider more frequently when vaccinated by pediatricians versus family physicians or in public facilities versus private practice. After controlling for poverty, immunization coverage varied only slightly with receipt of vaccines from a VFC-enrolled provider, receipt of vaccines within a medical home, and the number of parent-reported providers. Among children vaccinated within a medical home, those vaccinated solely by pediatricians were 1.63 times as likely to be 4:3:1:3 up-to-date than were those vaccinated solely by family physicians after removing the effects of poverty. RECOMMENDATIONS: Greater numbers of children are likely to benefit from an even higher participation rate among immunization providers in the VFC program, particularly among family physicians and private physicians. The public-private collaboration developed by the VFC program should be capitalized on so that public sector resources can help pediatricians and family physicians practice according to the Standards for Pediatric Immunization Practices.

Nosocomial transmission of hepatitis A in a pediatric hospital traced to an anti-hepatitis A virus-negative patient with immunodeficiency.

From July through October 1991, an outbreak of hepatitis A virus (HAV) infection involving 26 hospital staff, inpatients and household contacts occurred in a pediatric hospital. All ill staff members had cared for one inpatient who had profuse diarrhea with gross fecal contamination of the environment, negative HAV serology and idiopathic immunodeficiency. HAV infection in this patient was later confirmed by polymerase chain reaction. Among hospital staff HAV attack rates were highest in nursing personnel (15%). A retrospective cohort study of nurses found that the risk of infection was greatest in those who handled the source patient's soiled bed pad (relative risk, 6.7; 95% confidence intervals, 1.6, 27.8), diaper (relative risk, 5.4; 95% confidence intervals, 0.8, 39.2) or gown (relative risk, 2.9; 95% confidence intervals, 1.1, 7.8). Glove use during these activities was not associated with a lower risk of infection, possibly because of gross environmental contamination or less use than reported. This situation was unusual because the patient was HAV-infected but had negative serology, probably because of immunodeficiency. In situations of potentially extensive environmental contamination, such as with a diapered or incontinent patient with suspected or confirmed hepatitis A, careful attention to frequent handwashing is an essential protective measure; in addition strict glove use whenever entering the patient's room should be followed to provide additional protection.

Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States.

OBJECTIVE: We attempted to determine if an increase in resistance to ciprofloxacin occurred among nosocomial pathogens, especially Pseudomonas aeruginosa and Staphylococcus aureus. METHODS: We examined 1989-1992 ciprofloxacin susceptibility results from 8,517 P aeruginosa and 9,021 S aureus isolates associated with nosocomial infections reported to the National Nosocomial Infections Surveillance System. RESULTS: For S aureus, 27.1% of isolates were resistant to ciprofloxacin; of methicillin-resistant S aureus isolates, 80% also were resistant to ciprofloxacin. A logistic regression model found that ciprofloxacin resistance was more common among S aureus isolated from the urinary and respiratory tracts than from other sites of isolation, and among isolates that were methicillin resistant. After controlling for these factors, the model showed a 123% increase in the odds of ciprofloxacin resistance from 1989-1990 to 1991-1992. For P aeruginosa, 4.7% of the isolates were resistant to ciprofloxacin. Resistance varied by site of infection and rose most dramatically for respiratory tract isolates from 2.0% in 1989-1990 to 5.3% in 1991-1992. CONCLUSION: Resistance to ciprofloxacin is more frequent among nosocomial S aureus than among P aeruginosa and is increasing rapidly among S aureus isolates and from selected sites among P aeruginosa isolates.

Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis.

From January 1990 to December 1991, 16 patients with multidrug-resistant tuberculosis (MDR-TB) caused by Mycobacterium tuberculosis resistant to isoniazid, rifampin, and streptomycin were diagnosed at Elmhurst Hospital. Compared with other TB patients, MDR-TB patients were more likely to have human immunodeficiency virus (HIV) infection (14/16 vs. 21/204, P < .001) and a prior admission (10/16 vs. 3/204, P < .001). HIV-infected patients hospitalized for > 10 days within three rooms of an infectious MDR-TB patient had higher risk of acquiring MDR-TB than did HIV-infected patients with shorter hospitalizations or locations further from the MDR-TB patient(s) (6/28 vs. 2/90, P < .001). Isolates of 6 of 8 MDR-TB patients in a chain of transmission were identical by restriction fragment length polymorphism DNA typing. Ambulation on the wards of inadequately masked TB patients and lack of negative pressure in isolation rooms probably facilitated transmission. This report documents nosocomial transmission of MDR-TB and underscores the need for effective isolation practices and facilities in health care institutions.